Department of Health Sciences, University of Leicester, Leicester LE1 7RH, UK; Diabetes Research Centre, University of Leicester, Leicester LE5 4PW, UK.
Pharmacy Directorate, University Hospitals of North Staffordshire, Stoke-on-Trent ST4 6QG, UK.
J Clin Epidemiol. 2019 Feb;106:98-107. doi: 10.1016/j.jclinepi.2018.10.014. Epub 2018 Oct 29.
With older and aging populations, patients experience multiple chronic diseases at the same time. Individual chronic disease guidelines often recommend pharmacological therapies as a key intervention, resulting in patients being prescribed multiple regular medications for their different diseases. Although the term "polypharmacy" has been applied to the use of multiple medications, there is no consistent definition, and this term is now being used all inclusively. To improve both scientific rigor and optimal patient care, it is crucial that a standard terminology is used, which reclassifies the term "polypharmacy" into distinct phenotypes relating to the index chronic disease, additional conditions to the index (comorbidity), or the experience of multiple chronic conditions at the same time (multimorbidity). Using three exemplar index conditions; heart failure, type 2 diabetes, and breast cancer, we propose the reclassification of the term "polypharmacy" into three distinct phenotypes. First, index drug or multi-index drug therapy, where each index condition creates multiple drug use for that condition; second, codrug therapy, where addition of other comorbid conditions increases the multiple drug use and may influence the management of the index disease and third, multidrug therapy, where adult population with multimorbidity may be on many drugs. This article reviews guidelines for the individual exemplars to develop the basis for the new terms and then develops the pharmacoepidemiology of multiple drug use further by reviewing the evidence on the relationship between the phenotypic classification and important outcomes. The importance of standardizing "polypharmacy" terminology for the scientific agenda and clinical practice is that it relates to an index condition or disease safety outcomes including drug interactions, adverse side effects in hospital admissions, and related "polypill" concept.
随着人口老龄化,患者同时患有多种慢性疾病。个别慢性疾病指南通常推荐药物治疗作为主要干预措施,导致患者为不同的疾病开了多种常规药物。尽管“多药治疗”一词已用于多种药物的使用,但目前尚无一致的定义,而且现在这个术语被广泛使用。为了提高科学严谨性和最佳患者护理水平,使用标准术语至关重要,这将重新分类“多药治疗”术语,分为与索引慢性疾病、索引疾病的附加条件(合并症)或同时患有多种慢性疾病(多种合并症)相关的不同表型。我们以三个示例索引条件(心力衰竭、2 型糖尿病和乳腺癌)为例,提出将“多药治疗”术语重新分类为三种不同的表型。第一种是索引药物或多索引药物治疗,其中每个索引条件都会为该疾病使用多种药物;第二种是合并药物治疗,其中添加其他合并症会增加多种药物的使用,并可能影响索引疾病的管理;第三种是多药治疗,患有多种合并症的成年人群可能会使用多种药物。本文回顾了个别范例的指南,以制定新术语的基础,然后通过回顾关于表型分类与重要结果之间关系的证据,进一步发展多药物使用的药物流行病学。为科学议程和临床实践标准化“多药治疗”术语的重要性在于,它与索引条件或疾病安全结果相关,包括药物相互作用、住院期间的不良反应以及相关的“多药丸”概念。